Journal article
HLA Class II as Potential Target Antigen on Malignant B Cells for Therapy With Bispecific Antibodies in Combination With Granulocyte Colony-Stimulating Factor
Blood, Vol.87(9), pp.3803-3812
05/01/1996
DOI: 10.1182/blood.V87.9.3803.bloodjournal8793803
PMID: 8611706
Abstract
We have investigated the capacity of polymorphonuclear phagocytes (PMN) to lyse malignant B-cell lines using antibodies and antibody derivates to a range of different B-cell antigens. PMN were found to mediate lysis of all tested B-cell lines in the presence of HLA class II antibodies L227, L243, F3.3, and CR3/43. Target cell lysis was significantly enhanced when PMN isolated during granulocyte colony-stimulating factor (G-CSF) treatment were compared with PMN from healthy donors. Only G-CSF primed PMN, expressing FcγRI (CD64), lysed B cells in the presence of monoclonal antibody (MoAb) 1D10 or Lym-1 to HLA class II related epitopes. Remarkably, PMN were consistently unable to kill malignant B cells with antibodies to the B-cell related antigens CD19, CD20, CD21, CD37, and CD38. This target antigen restriction was not observed with mononuclear effector cells, which mediated cytotoxicity with antibodies to HLA class II, but also with mouse/human chimeric constructs to CD19, CD37, and CD38. Blocking studies with FcγR antibodies and reverse antibody-dependent cellular cytotoxicity (ADCC) experiments against FcγR antibody expressing hy-bridoma targets confirmed the pivotal role of FcγRI in enhanced killing by G-CSF primed neutrophils. Bispecific antibodies (BsAb) with one specificity for FcγRI, and another for a tumor associated antigen, offer an interesting approach to improve effector cell recruitment for immunotherapy. In our studies, very effective lysis was observed with G-CSF primed PMN and an [HLA class II x FcγRI] BsAb. The therapeutic implications of these findings and the possible use of BsAb in combination with G-CSF are discussed.
Details
- Title: Subtitle
- HLA Class II as Potential Target Antigen on Malignant B Cells for Therapy With Bispecific Antibodies in Combination With Granulocyte Colony-Stimulating Factor
- Creators
- David ElsasserThomas ValeriusRoland ReppGeorge J WeinerYashwant DeoJoachim R KaldenJan G.J. van de WinkelGeorge T StevensonMartin J GlennieMartin Gramatzki
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.87(9), pp.3803-3812
- Publisher
- Elsevier Inc
- DOI
- 10.1182/blood.V87.9.3803.bloodjournal8793803
- PMID
- 8611706
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 05/01/1996
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984094614802771
Metrics
10 Record Views